Anthem Biosciences Ltd
Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
- Market Cap ₹ 40,931 Cr.
- Current Price ₹ 730
- High / Low ₹ 802 / 702
- Stock P/E 90.6
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 28.5 %
- ROE 20.8 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 21.0%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | |
| 451 | 695 | 666 | 626 | 914 | 1,173 | |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% |
| 21 | 37 | 49 | 139 | 63 | 85 | |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 |
| Profit before tax | 121 | 366 | 546 | 497 | 477 | 657 |
| Tax % | 23% | 26% | 26% | 23% | 23% | 31% |
| 93 | 271 | 406 | 385 | 367 | 451 | |
| EPS in Rs | 110.62 | 319.74 | 462.09 | 6.75 | 6.57 | 8.07 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 14% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 4% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 21% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 114 | 112 | 112 |
| Reserves | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 |
| 159 | 100 | 35 | 126 | 239 | 113 | |
| 207 | 232 | 228 | 148 | 235 | 284 | |
| Total Liabilities | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 |
| 306 | 361 | 329 | 449 | 483 | 705 | |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 |
| 333 | 445 | 863 | 902 | 1,099 | 1,373 | |
| Total Assets | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 166 | 278 | 333 | 306 | 140 | 418 | |
| -109 | -196 | -205 | -376 | -221 | -152 | |
| -48 | -63 | 181 | 64 | -77 | -134 | |
| Net Cash Flow | 9 | 18 | 308 | -6 | -158 | 133 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 61 | 84 | 97 | 95 | 126 | 89 |
| Inventory Days | 186 | 29 | 52 | 139 | 129 | 167 |
| Days Payable | 87 | 50 | 50 | 77 | 61 | 54 |
| Cash Conversion Cycle | 160 | 63 | 99 | 156 | 193 | 202 |
| Working Capital Days | 20 | 27 | 75 | 112 | 128 | 134 |
| ROCE % | 55% | 51% | 28% | 24% | 28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
41m - An Earnings Conference Call to discuss the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025, is scheduled …
-
Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2025
1h - Board meeting on Aug 13 to approve Q1 FY26 financial results; trading window closed for insiders.
-
Intimation Under Regulation 30(5) Of The SEBI (Listing Obligation And Disclosures Requirements) Regulation, 2015
21 Jul - Authorized key managerial personnel for materiality determination and disclosures under SEBI LODR.
-
Announcement Under Regulation 7(1) Of The SEBI (Listing Obligation And Disclosures Requirements) Regulation, 2015
21 Jul - Kfin Technologies appointed as Registrar & Share Transfer Agent for Anthem Biosciences.
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
21 Jul - Anthem Biosciences files SEBI insider trading code and fair disclosure procedures as per regulations.
Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.